CELL DEATH DIS 润色咨询

Cell Death & Disease

出版年份:2010 年文章数:6499 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:2.8% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向:细胞死亡<br>经验分享:一审65天了,还没消息,彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束,开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收,核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向:肿瘤<br>经验分享:小cdd好还是cancer letters好?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]
    2023-05-18 36192448 来自湖南省

    偏重的研究方向:细胞死亡
    经验分享:一审65天了,还没消息,彻底躺平了

    11

    展开11条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向:细胞死亡<br>经验分享:一审65天了,还没消息,彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束,开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收,核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向:肿瘤<br>经验分享:小cdd好还是cancer letters好?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]
    2023-07-07 36192448 来自湖南省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:干细胞;细胞死亡
    经验分享:一审84天,二审7天,目前decision made 7天还没消息

    9

    展开9条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向:细胞死亡<br>经验分享:一审65天了,还没消息,彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束,开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收,核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向:肿瘤<br>经验分享:小cdd好还是cancer letters好?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]
    2022-07-12 ms9000001463682571

    4月12投稿
    4月13检查格式通过
    4月20指定责编
    4月23送外审
    4月25有审稿人同意审稿
    5月4号审稿结束,开始决定意见
    5月16日发邮件告知修回意见
    7月7日修回
    7月8日核对格式
    7月9日决定意见
    7月11日原则性接收,核对格式
    7月12日正式接收

    22

    展开22条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向:细胞死亡<br>经验分享:一审65天了,还没消息,彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束,开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收,核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向:肿瘤<br>经验分享:小cdd好还是cancer letters好?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]
    2024-03-25 124a8810m95(暂无昵称) 来自重庆

    偏重的研究方向:肿瘤
    经验分享:小cdd好还是cancer letters好?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向:细胞死亡<br>经验分享:一审65天了,还没消息,彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束,开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收,核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向:肿瘤<br>经验分享:小cdd好还是cancer letters好?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]
    2023-07-13 ms7000000921712169 来自广东省

    审稿速度:3.0 | 投稿命中率:25.0
    偏重的研究方向:呼吸疾病
    经验分享:刚刚中了一篇,比较顺利

    5

    展开5条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向:细胞死亡<br>经验分享:一审65天了,还没消息,彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束,开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收,核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向:肿瘤<br>经验分享:小cdd好还是cancer letters好?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]
    2024-02-06 ms3000001660419742 来自台湾省

    偏重的研究方向:幹細胞
    经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ

    5

    展开5条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向:细胞死亡<br>经验分享:一审65天了,还没消息,彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束,开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收,核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向:肿瘤<br>经验分享:小cdd好还是cancer letters好?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]
    2023-07-01 Shawnwang 来自广东省

    偏重的研究方向:细胞死亡
    经验分享:刚刚submit,上帝保佑,沾沾大家的喜气

    10

    展开10条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向:细胞死亡<br>经验分享:一审65天了,还没消息,彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束,开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收,核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向:肿瘤<br>经验分享:小cdd好还是cancer letters好?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]
    2024-01-16 ms4000000731438466 来自天津

    偏重的研究方向:肿瘤
    经验分享:提交10天,显示状态为Decision made什么情况?

    6

    展开6条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向:细胞死亡<br>经验分享:一审65天了,还没消息,彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束,开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收,核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向:肿瘤<br>经验分享:小cdd好还是cancer letters好?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]
    2024-03-05 超超不吵吵 来自湖南省

    投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向:细胞死亡<br>经验分享:一审65天了,还没消息,彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束,开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收,核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向:肿瘤<br>经验分享:小cdd好还是cancer letters好?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]
    2022-10-02 ms4000000661887175

    请问有投综述的吗?从提交文章到有结果大概是什么流程?

    3

    展开3条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分